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a  b  s  t  r  a  c  t
In  patients  with myelodysplastic  syndromes  (MDS)  iron  overload  caused  by long-term  red  blood  cell
transfusions  is  an  important  factor for  comorbidity  especially  in  low-risk  MDS. In  this  report  we  present
the results  of  a comparative  study  based  on  colony  formation  assays  of  hematopoietic  cells  in MDS
patients  with  and  without  iron  overload.  We  demonstrate  that  iron  overload  suppresses  the  proliferation
of  erythroid  progenitors  cells  (BFU-E),  while  the  myeloid  compartment  (CFU-GM)  was  not  found  to  be
affected.  Even  patients  with  slightly  elevated  ferritin  values  show  an  impaired  proliferation  capacity  ineywords:
ron overload
olony forming assays
FU-E
FU-GM
comparison  to patients  with  normal  ferritin  levels.  Furthermore,  we  show  that  this  negative  impact  is
reversible by  sufﬁcient  iron  chelation  therapy.
© 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.roliferation capacity
helation therapy
. Introduction
Myelodysplastic syndromes (MDS) are a heterogeneous group
f clonal hematopoietic stem cell disorders leading to ineffec-
ive hematopoesis with peripheral cytopenias [1–4]. The patients
resent with anemia and consecutive fatigue, dyspnea as well as
n increased risk for cardiac events. Long-term red blood cell (RBC)
ransfusion therapy can be expected in 40–80% of patients [5,6].
ne RBC unit contains approximately 200 mg  iron, implicating a
igniﬁcant parenteral iron input with each transfusion [7]. The
hreshold for clinically relevant secondary iron overload is deﬁned
y a serum ferritin of 1000 g/l [8],  which is reached after a median
umber of 21 RBC units and a median period of 10.8 months [9].
In MDS  transfusional iron overload is associated with increased
orbidity and mortality due to cardiac and/or hepatic damage [9].
 Statement of prior presentation: Parts of this study were presented as poster
resentation at the ASH Annual Meeting 2008, Blood 2008 [abstract 2694] and at
he ASH Annual Meeting 2009, Blood 2009 [abstract 3826].
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Open access under CC BY-NC-ND license.Malcovati et al. [10] described transfusion dependency in MDS  as
an independent marker with negative prognostic impact. Iron over-
load can effectively be treated by chelation therapy. Thus, Leitch
[11], Rose et al. [12] and Fox et al. [13] collected data indicating a
survival beneﬁt in low-risk MDS  patients who received adequate
chelation therapy.
In 1996, Jensen et al. [14] for the ﬁrst time demonstrated that
chelation therapy can improve the transfusion need of patients
with MDS. These ﬁndings were conﬁrmed by Messa et al. [15]
2003 and Gattermann et al. [16] 2010 who  observed improved
hemoglobin levels, decreased transfusion requirement and reduced
iron burden under sufﬁcient chelation therapy.
As iron also accumulates in the bone marrow, the improvement
of transfusion dependence by adequate iron chelation therapy sug-
gests that iron overload might not only damage hepatocytes and
cardiomyocytes, but also bone marrow progenitor cells. While
the proliferative capacity of the hematopoietic progenitor cells is
impaired by the disease itself [17], toxic iron overload might addi-
tionally deteriorate erythropoiesis in the MDS  marrow as a “second
hit”.
To evaluate the proliferative capacity of hematopoietic progen-
itor cells and a putative impact of iron we performed 475 in vitro
colony formation assays from peripheral blood samples of 101
MDS  patients with and without iron overload to assess the colony
forming capacity [18]. Abnormal or dysplastic colony formation, as
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Table  1
Patient characteristics (n = 52).
Age (years) [range] 69 [39–86]
Male/female 30/22
WHO
5q-Syndrome 4 (7.5%)
RA/-RS 18 (35.0%)
RCMD/-RS 16 (30.5%)
RAEB I/II 11 (21.0%)
Unclassiﬁed 3 (6.0%)
IPSS
Low 15 (29%)
Int-I 25 (48%)
Int-II 9 (17%)
High 3 (6%)
Cytogenetics
Low 42 (81%)
Intermediate 3 (6%)
High 7 (13%)
Blood counts [range]
Median hemoglobin (g/dl) 9.1 [5.8–13.2]
Median leucocytes (103/l) 2.9 [0.5–30]
Median neutrophils (%) 43 [<2–72]
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cMedian platelets (103/l) 78 [7–529]
Median ferritin (g/l) 674 [11–6267]
ell as decreased numbers of burst forming units-erythroid (BFU-
) are typical ﬁndings in MDS  patients [19,20].  In colony assays,
FU-E represent early progenitors of red blood cells, and colony
orming units granulocyte-macrophage (CFU-GM) originate from
yeloid progenitors [19]. This study was performed to investi-
ate whether the proliferative capacity of bone marrow progenitor
ells is inﬂuenced by iron overload in MDS. Furthermore, repeated
ntraindividual analyses were employed to follow the develop-
ent of proliferative capacity of hematopoietic progenitors of MDS
atients receiving chelation therapy.
. Materials and methods
.1. Patients
In 101 MDS  patients a total number of 475 colony assays were performed. All
atients with hepatic diseases, active infections or elevated values of C-reactive
rotein (CRP) or procalcitonin (PCT) at the time of sampling, chemotherapy or epi-
enetic therapy during the last 6 months, or receiving cytokine and/or corticoid
herapy within the last 3 months were excluded from the study. Using these criteria
or ﬁnal evaluation, samples from 52 MDS  patients with or without transfusional
ron overload determined by serum ferritin levels were available for analysis (Table
 suppl. data), as characterized according to age, sex, World Health Organization
WHO) criteria [20], International Prognostic Scoring System (IPSS) [21], cytogene-
ics [22], median peripheral blood counts and ferritin (Table 1). Using serum ferritin
s  a marker for body iron storage is an easy, cheap and well-established method for
linical monitoring [7].  At our institution, the normal ferritin values were deﬁned
y  20–250 g/l.
ig. 1. (a) Burst forming units-erythroid (BFU-E): colony (*) in the lower right, parallel gr
olony (*) in the upper left, parallel growth of cluster (→).earch 37 (2013) 327– 332
Supplementary material related to this article found, in the online version, at
http://dx.doi.org/10.1016/j.leukres.2012.11.005.
Informed consent was obtained from every patient in accordance with the mod-
iﬁed Declaration of Helsinki.
2.2. Colony formation assays
In 101 MDS  patients 475 colony assays from peripheral blood were performed
according to the protocols described before [22]: Peripheral blood samples were
diluted with buffer medium PBS (Biotec, Germany), mononuclear cells were isolated
by  density gradient centrifugation (Lymphoprep, Axis Shield, Norway). After several
washing steps and RPMI dilution (Invitrogen, Germany), the mononuclear cells were
counted by neubauer ﬁeld (1.5 ×105 peripheral blood cells/culture dish) and cul-
tivated in a 1%-medium of methylcellulose. To stimulate BFU-E growth 25 ng/ml
SCF  (R&D Systems, Germany) and 50 ng/ml erythropoetin (Roche, Germany) were
applied. To stimulate CFU-GM growth 25 ng/ml SCF, 50 ng/ml IL-3 (R&D Systems,
Germany), 50 ng/ml GM-CSF (R&D Systems, Germany) and 50 ng/ml G-CSF (R&D
Systems, Wiesbaden, Germany) were applied. The plates were incubated at 37 ◦C
under a fully humidiﬁed atmosphere and 5% CO2.
The BFU-E (Fig. 1a) and CFU-GM (Fig. 1b) were analyzed at day 12–16 (median
day 14) by the same experienced technician at our institution (U.S.). The normal
range of BFU-E (healthy controls) at our lab was 40 ± 25/1 × 105 cells. Cell aggregates
of  more than 50 cells were scored as colonies, cell aggregates of less than 50 cells
were counted as clusters. Patients with a diffuse growth pattern or leukemic cluster
formation were excluded from ﬁnal analysis [23].
2.3. Statistical evaluation
The statistical evaluation was performed with SAS 9.1 software (SAS Insti-
tute Inc., Cary NC, USA) using Wilcoxon–Mann–Whitney tests and chi-squared
tests (F.K.). Multiplicity adjustments were performed by Bonferroni correction. The
results were regarded as signiﬁcant if the p-value was  below 5%.
3. Results
3.1. Patients characteristics
The ﬁnal study cohort consisted of 52 MDS patients with and
without iron overload (Table 1). The cohort could be divided
into two groups according to serum ferritin levels: 14 patients
had normal ferritin levels (<250 g/l) with a median ferritin of
92 g/l (range 11–213 g/l), and 38 patients showed elevated fer-
ritin values (>250 g/l) with a median level of 869 g/l (range
273–6267 g/l). These two  groups were characterized and statis-
tically compared according to age, sex, WHO, IPSS, cytogenetics,
transfusion dependence and peripheral blood counts (Table 2).Comparing the patients with normal (n = 14) and elevated
(n = 38) ferritin values, there were no signiﬁcant differences in the
WHO subtypes (p = 0.57) and IPSS (p = 0.41), in the cytogenetic risk
groups (p = 0.71), age (p = 0.7) or gender (p = 0.19).
owth of cluster (→). (b) Colony forming units granulocyte-macrophage (CFU-GM):
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Table 2
Characteristics of MDS  patients with normal and elevated ferritin values (n = 52).
Normal ferritin (<250 g/l) Elevated ferritin (>250 g/l) p-Value*
Patients in total 14 38
Male/female 8/6 24/14 0.19
Median age (years) [range] 67 [39–80] 70 [39–80] 0.7
WHO  [n(%)] 0.57
5q-Syndrome 2 (14) 2 (5)
RA/-RS 4 (29) 14 (37)
RCMD/-RS 4 (28) 12 (32)
RAEB I/II 4 (29) 7 (18)
Unclassiﬁed 0 (0) 3 (8)
IPSS  [n(%)] 0.41
Low 3  (21) 12 (32)
Intermediate-I 7 (50) 18 (47)
Intermediate-II 4 (29) 5 (13)
High  0 (0) 3 (8)
Cytogenetics [n(%)] 0.71
Low 12 (86) 30 (79)
Intermediate 1 (7) 2 (5)
High 1 (7) 6 (16)
Transfusion dependence [range]
Mean RBC per month 0 [0] 3.3 [1–7]
Mean total RBC 4 [2–6] 25.6 [2–162]
Mean total PC 2 [2] 3.8 [1–9]
Blood values [range]
Median ferritin (g/l) [range] 92 [11–213] 869 [273–6267] 0.0008
Median hemoglobin (g/dl) 10.8 [6.9–13.2] 9 [5.8–12.5] 0.0033
Median leucocytes (103/l) 2.65 [1.1–8.5] 3.04 [0.5–30] 0.63
Median neutrophils (%) 42 [<2–60] 43.6[5–72] 0.4
Median platelets (103/l) 62 [19–444] 80.3 [7–529] 0.87
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BA: refractory anemia; RS: with ringsideroblasts; RCMD: refractory cytopenias wit
oncentrate; PC: platelet concentrate.
* Evaluated by following tests: age and blood values by t-test; sex, WHO, IPSS, cy
.2. Proliferation of BFU-E and CFU-GM in MDS  patients
ccording to serum ferritin levels
Out of 14 patients with normal ferritin, none was transfusion
ependent for RBC. In 30 of 38 patients with elevated ferritin values,
ata of transfusion requirement were available: 18 of 30 patients
ad received RBC continuously (mean 3.3 RBC/month).
BFU-E were evaluated in 14 patients with normal and 38
atients with elevated serum ferritin levels. CFU-GM were eval-
ated in 12 patients with normal and 32 patients with elevated
erum ferritin levels. Eight patients showed a cluster growth in
FU-GM, so the CFU-GM results were excluded from the study.
he median numbers of BFU-E and CFU-GM of the 2 groups were
ompared (Table 3): Patients with normal ferritin levels showed
igniﬁcantly higher numbers of BFU-E (median 3.5 versus 0.5) than
atients with elevated ferritin levels (p = 0.0013, Fig. 2a). How-
ver, there were no differences (median 6.8 versus 3.0) for CFU-GM
p = 0.57, Fig. 2b).
Out of 38 patients with elevated ferritin levels, 16 (42%) had
erritin values above 1000 g/l, and 22 (58%) showed ferritin val-
es between 250 and 1000 g/l. Comparing those 2 subgroups
f patients with normal ferritin (n = 14), there was  a decrease in
FU-E growth, and this was statistically signiﬁcant between the
roup with normal ferritin and ferritin values of 250–1000 g/l
able 3
omparison of BFU-E and CFU-GM numbers in MDS  patients with normal (n = 14) and ele
Valid N Mean Median 
Ferritin < 250 g/l
BFU-E 14 10.7 3.5 
CFU-GM 12 13.2 6.8 
Ferritin > 250 g/l
BFU-E 38 8.9 0.5 
CFU-GM 32 18.9 3 
FU-E: burst forming units-erythroid. CFU-GM: colony forming units granulocyte-macrotilineage dysplasia; RAEB: refractory anemia with blast excess; RBC: red blood cell
etics by chi square test; blood values were determined before RBC transfusion.
(p = 0.0012; Fig. 2c, Table B suppl. data). The comparison of BFU-E
numbers between the groups “normal ferritin” and “elevated fer-
ritin > 1000 g/l” was formally not statistically signiﬁcant at the
5% level. But regarding the median BFU-E numbers of 3.5 and
1, it was  remarkably decreased in the subgroup with elevated
ferritin > 1000 g/l. The non-signiﬁcance can be explained by the
relatively small sample size and the conservative Bonferroni cor-
rection.
Supplementary material related to this article found, in the
online version, at http://dx.doi.org/10.1016/j.leukres.2012.11.005.
3.3. Effect of iron chelation therapy on BFU-E proliferation
From 5 MDS  patients (ID 17, 34, 42, 45 and 75) at least
3 consecutive samples were available for serial investigations
(Table 4), covering a median observation period of 25 months
(range 14–47 months). A median number of 6 colony assays
(range 3–16) were performed. Initially, all patients showed signiﬁ-
cantly elevated serum ferritin values with a median of 2274 g/l
(range 508–5906 g/l). All 5 patients received chelation ther-
apy with deferasirox with a mean dosage of 2500 mg/d (range
1625–3000 mg/d) during the observation time, some of them
started long ago with deferoxamine or deferiprone (Table 4). In
all 5 patients the serum ferritin levels decreased under chelation
vated (n = 38) ferritin values.
Minimum Maximum Std. dev.
0 76 19.6
0.5 38.5 13.2
0 250 40.5
0 120 29.6
phage.
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Fig. 2. (a) Proliferation of BFU-E in patients with normal (n = 14) and elevated (n = 38) ferritin values (p = 0.0013). (b) Proliferation of CFU-GM in patients with normal (n = 12)
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nnd  elevated (n = 32) ferritin values (p = 0.57). (c) Proliferation of BFU-E in patients
etween 250 and 1000 g/l (n = 22) and with elevated ferritin values above 1000 
erritin > 1000 g/l; p3: ferritin 250–1000 g/l versus ferritin > 1000 g/l.
herapy. In 2 patients stable numbers of BFU-E were observed under
helation therapy (ID 34 and 45), in the series of one patient we
oticed a transitory increase of BFU-E (ID 42, Fig. 3a), while in the
amples from 2 patients (ID 17 and 75, Fig. 3b) an onlasting increase
n BFU-E numbers was documented. A decrease in BFU-E numbers
as not seen in any of the longitudinal series. With regard to trans-
usion dependence, data were available in 3 of these 5 patients (ID
7, 34 and 42). Two patients (ID 17 and 42) experienced stable
isease, and one patient (ID 34) became completely transfusion
ndependent after 10 months of chelation therapy, which is still
nlasting.
. DiscussionRBC transfusions are an essential element of supportive care in
nemic MDS  patients. Especially in low-risk MDS  patients with
ong overall survival iron overload is a common problem lead-
ng to organ dysfunction and increased mortality rates [24]. A
ig. 3. Sequential analyses of colony assays for BFU-E numbers and ferritin values under c
umbers, (b) Patient ID 75: decreasing ferritin values and increasing BFU-E numbers.normal ferritin (FT) values below 250 g/l (n = 14), slightly elevated ferritin values
= 16): p1: normal ferritin versus ferritin 250–1000 g/l; p2: normal ferritin versus
signiﬁcant survival advantage of low-risk MDS  patients receiving
iron-chelation therapy compared to untreated patients (124 versus
53 months, p < 0.0003) was  already described by Rose et al. [12].
In the situation of iron overload organ cell damage is induced by
oxyradicals [25], which originate from non-transferrin bound free
iron ions exceeding the capacities of iron binding proteins. Non-
transferrin bound iron can be sufﬁciently eliminated by chelation
therapy [26]. Jensen et al. [14] and Messa et al. [15] showed that
the transfusion requirement of MDS  patients decreases under an
efﬁcient chelation therapy and explained this by an improvement
of the function of erythroid progenitor cells.
Comparing the numbers of BFU-E in patients with and without
iron overload, we demonstrate that in patients with elevated fer-
ritin values (>250 g/l) the numbers of BFU-E were signiﬁcantly
reduced (p = 0.0013), while CFU-GM counts showed no differences
between the two  groups (p = 0.57). Both groups were comparable
according to WHO, IPSS, cytogenetics, age or gender (Table 2) and
did not differ signiﬁcantly.
helation therapy: (a) Patient ID 42: decreasing ferritin values and increasing BFU-E
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Samples from patients with ferritin values between 250 and
1000 g/l had signiﬁcantly reduced BFU-E growth numbers com-
pared to samples from patients with normal ferritin values
(p = 0.0012). Interestingly, the suppression of erythroid progenitor
proliferation capacity was even detectable in patients with slightly
elevated ferritin levels, in whom a chelation therapy was not yet
indicated according to international consensus guidelines [8].
For the ﬁrst time, we were able to demonstrate an iron overload-
dependent suppression of erythropoiesis in MDS  patients by
counting colony forming units as a read-out for the proliferative
capacity of hemtopoietic progenitors. Iron overload had more inﬂu-
ence on erythroid than on myeloid progenitor cells. Furthermore,
we demonstrated a signiﬁcant impact of iron on the proliferative
capacity even in patients with moderate iron overload and without
clinical indication for chelation therapy (ferritin 250–1000 g/l).
Jensen et al. [14] and Messa et al. [15] described a decreased need
of RBC transfusions under chelation therapy. Here we provide evi-
dence, that the negative impact of toxic iron on the proliferation
of erythroid progenitor cells may  be in part reversible. All patients
of our cohort treated with chelation therapy showed decreasing
ferritin levels. In two (ID 17 and 75) of ﬁve patients there was  an
on-lasting increase of BFU-E counts, another one (ID 42) showed a
transient increase, and two patients (ID 34 and 45) showed stable
BFU-E counts. In three (ID 17, 34 and 42) of those patients the trans-
fusion requirement decreased under chelation therapy accordingly.
One patient (ID 34) with an initial serum ferritin of 1955 g/l
became transfusion independent after 10 months of chelation ther-
apy. Okabe et al. [27] reported on a 75-year-old woman with MDS
RCMD, who  became transfusion independent after 17 months of
treatment with deferasirox. In that case, the initial ferritin was
much higher than in our patient (1955 g/l versus 4084 g/l), and
the time needed to achieve transfusion independence was longer
than in our patient. In both patients the only therapeutic procedure
was chelation therapy. Time seems to be an important factor in
recuperation of the proliferation capacity of hematopoiesis. Jensen
et al. [14] described a maximum effect on transfusion requirement
after 1.5 years. In accordance with these data, our study showed
an increase of BFU-E in a sense of a recovered hematopoiesis not
earlier than 12 months after onset of chelation therapy.
In summary, we  here provide for the ﬁrst time evidence that iron
overload is associated with reduced proliferation of BFU-E in MDS
patients. This means, that RBC transfusions as the main part of best
supportive care additionally worsen the already poor hematopoi-
etic proliferation capacity in MDS  patients. The ﬁndings should be
considered together with other clinical parameters for an early,
effective and on-lasting chelation therapy for MDS  patients with
need for erythrocyte transfusions.
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